{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:22:40Z","timestamp":1762842160818,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2018]]},"DOI":"10.1016\/j.ctarc.2018.10.001","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T13:07:42Z","timestamp":1539695262000},"page":"37-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Abiraterone in metastatic castration-resistant prostate cancer: Efficacy and safety in unselected patients"],"prefix":"10.1016","volume":"17","author":[{"given":"Gr\u00e9goire","family":"Marret","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovic","family":"Doucet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Culine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ctarc.2018.10.001_bib0001","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2018.10.001_bib0002","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/pcan.2014.35","article-title":"Who dies from prostate cancer","volume":"17","author":"Patrikidou","year":"2014","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"5","key":"10.1016\/j.ctarc.2018.10.001_bib0003","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/annonc\/mds624","article-title":"Prostate cancer: ESMO Consensus Conference Guidelines 2012","volume":"24","author":"Horwich","year":"2013","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2018.10.001_bib0004","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","article-title":"Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017","volume":"73","author":"Gillessen","year":"2017","journal-title":"Eur. Urol."},{"issue":"9","key":"10.1016\/j.ctarc.2018.10.001_bib0005","first-page":"1617","article-title":"Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel","volume":"50","author":"Fitzpatrick","year":"2014","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"issue":"12","key":"10.1016\/j.ctarc.2018.10.001_bib0006","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1158\/1078-0432.CCR-10-2815","article-title":"Targeting continued androgen receptor signaling in prostate cancer","volume":"17","author":"Massard","year":"2011","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"27","key":"10.1016\/j.ctarc.2018.10.001_bib0007","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2011.35.2005","article-title":"Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically","volume":"29","author":"Ryan","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.ctarc.2018.10.001_bib0008","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-07-5997","article-title":"Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer","volume":"68","author":"Locke","year":"2008","journal-title":"Cancer Res."},{"issue":"7560","key":"10.1016\/j.ctarc.2018.10.001_bib0009","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature14406","article-title":"Conversion of abiraterone to D4A drives antitumor activity in prostate cancer","volume":"523","author":"Li","year":"2015","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.ctarc.2018.10.001_bib0010","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2018.10.001_bib0011","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2018.10.001_bib0012","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2018.10.001_bib0013","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2018.10.001_bib0014","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2018.10.001_bib0015","first-page":"228","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"issue":"3","key":"10.1016\/j.ctarc.2018.10.001_bib0016","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.ctarc.2018.10.001_bib0017","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2018.10.001_bib0018","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2016.02.035","article-title":"Low Incidence of corticosteroid-associated adverse events on long-term exposure to low-dose prednisone given with abiraterone acetate to patients with metastatic castration-resistant prostate cancer","volume":"70","author":"Fizazi","year":"2016","journal-title":"Eur. Urol."},{"issue":"10","key":"10.1016\/j.ctarc.2018.10.001_bib0019","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.ctarc.2018.10.001_bib0020","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1158\/1078-0432.CCR-11-0815","article-title":"Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response","volume":"17","author":"Ryan","year":"2011","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer. Res."},{"key":"10.1016\/j.ctarc.2018.10.001_bib0021","first-page":"44","article-title":"Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors","volume":"61","author":"Fuerea","year":"2016","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"issue":"5","key":"10.1016\/j.ctarc.2018.10.001_bib0022","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.eururo.2017.09.022","article-title":"Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for metastatic castration-na\u00efve prostate cancer in the GETUG-AFU 15 Phase 3 trial","volume":"73","author":"Lavaud","year":"2017","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.ctarc.2018.10.001_bib0023","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.eururo.2016.06.033","article-title":"Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302","volume":"71","author":"Bono","year":"2017","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.ctarc.2018.10.001_bib0024","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.eururo.2014.04.015","article-title":"Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies","volume":"68","author":"Al Nakouzi","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ctarc.2018.10.001_bib0025","article-title":"Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for \u226524 weeks in Europe","author":"Bono","year":"2017","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.ctarc.2018.10.001_bib0026","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.eururo.2017.03.007","article-title":"Clinical outcomes from androgen signaling-directed therapy after treatment with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer: post Hoc analysis of COU-AA-302","volume":"72","author":"Smith","year":"2017","journal-title":"Eur. Urol."},{"issue":"12","key":"10.1016\/j.ctarc.2018.10.001_bib0027","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1470-2045(13)70424-8","article-title":"Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial","volume":"14","author":"Basch","year":"2013","journal-title":"Lancet Oncol."},{"issue":"17","key":"10.1016\/j.ctarc.2018.10.001_bib0028","first-page":"3648","article-title":"Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy","volume":"49","author":"Harland","year":"2013","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294218300583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294218300583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:17:48Z","timestamp":1762841868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294218300583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":28,"alternative-id":["S2468294218300583"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2018.10.001","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abiraterone in metastatic castration-resistant prostate cancer: Efficacy and safety in unselected patients","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2018.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}